U.S. Markets closed

Why Wall Street Thinks This Biotech Stock Can Triple Your Money

·4 min read
Why Wall Street Thinks This Biotech Stock Can Triple Your Money
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Axsome Therapeutics (NASDAQ: AXSM) is close to earning approval for a new depression drug that could generate billions in annual revenues. Unfortunately, the proposed action date for the Food and Drug Administration (FDA) to grant approval already came and went. Consensus price targets suggest Axsome Therapeutics' stock price could rise 197% if most investors begin seeing the company in the same light as the investment-bank analysts who follow it closely.